Ageing, Tuberculosis
Conditions
Keywords
Ageing, Tuberculosis, Interferon gamma releasing tests
Brief summary
Background: Diagnosis and screening for latent tuberculosis in old patients is of special interest in regards of the morbidity-mortality of this disease in that context. TB-infection diagnosis based on immunological memory detection can be impaired with age. New blood tests (QFTB-G and T-SPOT.TB) specific for MTB infection have not been evaluated in those old patients.The primary endpoint of this study is the evaluation of the IGRAS for active TB diagnosis in patients above 75 years old.
Detailed description
In vitro Interferon Gamma releasing Assay (IGRA) are recommended for LTBI screening as or instead of TST, but there accuracy in those old patients are not known: as immune responses are impaired in elderly and some of them have already met M tuberculosis before active antibiotherapy exists.The aim of this study is to evaluate characteristics of the two commercials tests IGRA T-spot-TB® and Quantiferon-TB-gold- in tube® and TST in old patients with or without active Tuberculosis. Principal outcome: \- 3 tests performance for active TB diagnosis in patients older than 75 years-old Secondary outcomes : * concordance between IGRAs. * non-concordant results analysis * concordance of IGRAs results with time of TB-infection * biobank Methodology :Diagnostic test performance study
Interventions
OTHERBlood samples
4 blood tubes of lithium heparinate (5ml) 3 blood tubes of QTF-G-IT (1ml) 1 blood dry tube (5ml)
Sponsors
Assistance Publique - Hôpitaux de Paris
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
75 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \> 75 years * Consent signed * hospitalized patient with start treatment of Tuberculosis disease * French social right
Exclusion criteria
* Tuberculosis disease treatment since 7 days * No 3 months follow-up possible * Immunosuppression
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of positive, indeterminate, negative tests in each group | month27 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Test results in clinical LTBI patients | month 27 | — |
| Correlation with TB-infection date | month 27 | Test results (positive/negative) according to LTBI date |
| Blood samples collection in order to test new hypothesis in patients with non-concordant results | month 27 | — |
| Performance comparison between tests (T-SPOT.TB®, Quantiferon-Gold-IT®) | month 27 | — |
Countries
France
Outcome results
None listed